已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Effects of zoledronate on bone mineral density and bone turnover after long-term denosumab therapy: Observations in a real-world setting

德诺苏马布 医学 骨矿物 骨重建 中止 股骨颈 骨质疏松症 泌尿科 唑来膦酸 养生 内科学
作者
Judith Everts‐Graber,Stephan Reichenbach,Brigitta Gahl,HansJörg Häuselmann,Hans‐Rudolf Ziswiler,Ueli Studer,Thomas Lehmann
出处
期刊:Bone [Elsevier]
卷期号:163: 116498-116498 被引量:17
标识
DOI:10.1016/j.bone.2022.116498
摘要

The rebound effect after denosumab discontinuation is lessened with subsequent zoledronate therapy. However, it is unclear whether this mitigation is sufficient after long-term denosumab treatment. This retrospective observational study analysed bone mineral density (BMD) and bone turnover marker (BTM) changes after denosumab therapy according to treatment duration and subsequent zoledronate regimen. We measured the outcomes of 282 women with postmenopausal osteoporosis who discontinued denosumab and received zoledronate 6 months later. In patients with longer denosumab therapy (≥5 years), BTMs were measured every 3 months and a second zoledronate infusion was administered if BTM levels increased by ≥2-fold. The BMD of all women was measured before denosumab therapy, at the last injection and 1 to 2 years after the first zoledronate. Bone loss after switching from denosumab to zoledronate was higher in patients with 10 ± 2 denosumab injections (n = 84) compared to 5 ± 2 injections (n = 144, p < 0.001 for lumbar spine and femoral neck), but there was no further increase with treatment durations of ≥15 ± 2 injections (n = 54, p = 0.35 and p = 0.20, respectively). BTMs in patients with ≥10 denosumab injections were elevated 6 months after zoledronate in some patients, but not all. Twenty-four women received a second zoledronate dose 6 months after the first one. BTMs in these patients were subsequently lower, but bone loss at both the lumbar spine and hip was comparable to that in patients with only one zoledronate dose (p = 0.37 for lumbar spine and p = 0.97 for femoral neck). Rebound-associated bone loss reached a plateau after denosumab treatment durations of 4–6 years, irrespective of the frequency of subsequent zoledronate therapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
DcQiu科研小白完成签到,获得积分10
1秒前
苞大米完成签到,获得积分10
2秒前
柯语雪完成签到 ,获得积分10
3秒前
GG完成签到 ,获得积分10
3秒前
上官若男应助维夏十一采纳,获得10
4秒前
老迟到的土豆完成签到 ,获得积分10
5秒前
迷糊完成签到,获得积分10
7秒前
弩年完成签到,获得积分10
8秒前
Demi_Ming完成签到,获得积分10
10秒前
申木完成签到 ,获得积分10
13秒前
15秒前
克泷完成签到 ,获得积分10
17秒前
宁夕完成签到 ,获得积分10
19秒前
zhl完成签到,获得积分10
19秒前
维夏十一发布了新的文献求助10
20秒前
23秒前
贺天发布了新的文献求助10
23秒前
小文子完成签到 ,获得积分10
24秒前
24秒前
yqf完成签到,获得积分10
26秒前
stresm发布了新的文献求助10
30秒前
忧郁荔枝完成签到 ,获得积分10
32秒前
kannnliannn完成签到 ,获得积分10
32秒前
deeferf完成签到 ,获得积分10
32秒前
狗十七完成签到 ,获得积分10
33秒前
居蓝完成签到 ,获得积分10
34秒前
凶狠的寄风完成签到 ,获得积分10
37秒前
keyanzhang完成签到 ,获得积分10
43秒前
mmmm完成签到,获得积分10
43秒前
宋芽芽u完成签到 ,获得积分10
44秒前
能干的语芙完成签到 ,获得积分10
44秒前
master-f完成签到 ,获得积分10
45秒前
C9完成签到 ,获得积分10
46秒前
Little2完成签到,获得积分10
48秒前
研友_LmgOaZ完成签到 ,获得积分0
49秒前
YZY发布了新的文献求助20
49秒前
大米发布了新的文献求助10
51秒前
闫_闫完成签到,获得积分10
51秒前
CodeCraft应助潇洒的凡灵采纳,获得10
53秒前
Lhhht完成签到,获得积分10
53秒前
高分求助中
Licensing Deals in Pharmaceuticals 2019-2024 3000
Cognitive Paradigms in Knowledge Organisation 2000
Effect of reactor temperature on FCC yield 2000
Very-high-order BVD Schemes Using β-variable THINC Method 1020
Near Infrared Spectra of Origin-defined and Real-world Textiles (NIR-SORT): A spectroscopic and materials characterization dataset for known provenance and post-consumer fabrics 610
Promoting women's entrepreneurship in developing countries: the case of the world's largest women-owned community-based enterprise 500
Shining Light on the Dark Side of Personality 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3307154
求助须知:如何正确求助?哪些是违规求助? 2940961
关于积分的说明 8499733
捐赠科研通 2615177
什么是DOI,文献DOI怎么找? 1428712
科研通“疑难数据库(出版商)”最低求助积分说明 663493
邀请新用户注册赠送积分活动 648382